Mirabegron and antimuscarinic use in frail overactive bladder patients in the United States Medicare population.

ABSTRACT:

Introduction

Overactive bladder (OAB) and frailty are independently associated with patient burden. However, economic burden and treatment-taking behavior have not been well characterized among frail patients with OAB, which, given the varying safety and tolerability profiles of available treatments, is crucial.

Objectives

To assess costs, health care resource utilization, treatment-taking behavior (persistence and adherence) to OAB medication in older, frail OAB patients.

Methods

This was a retrospective cohort study using international business machines MarketScan Medicare Supplemental claims data. Eligible frail patients (per Claims-based Frailty Index score) initiating mirabegron were 1:2 propensity score matched (based on age, sex, and other characteristics) with

SUBMITTER: Johnson TM 

PROVIDER: S-EPMC9826123 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature